Premium
Phase II study of recombinant human interferon gamma (S‐6810) on renal cell carcinoma. Summary of two collaborative studies
Publication year - 1987
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19870901)60:5<929::aid-cncr2820600502>3.0.co;2-n
Subject(s) - medicine , renal cell carcinoma , leukopenia , interferon , adverse effect , recombinant dna , carcinoma , interferon gamma , anorexia , gastroenterology , immunology , chemotherapy , cytokine , biochemistry , chemistry , gene
Seventeen institutions in Japan evaluated the antitumor activity of recombinant human interferon gamma (S‐6810) as a new modality for advanced renal cell carcinoma. The response rate for 32 evaluable patients who received continuous daily administration of 8 × 10 6 U/m 2 to 12 × 10 6 U/m 2 of interferon for 4 weeks was 9.4%. Six of 30 patients (20%) were demonstrated responders in the case of the intermittent adminstration of 40 × 10 6 U/m 2 of interferon on each of days 1 to 5, 15 to 19, 29, 31, 33, 43, 45, and 47 over an 8‐week period. One of the responders achieved a complete response (CR). The patients tolerated this dose of interferon gamma well. Sites that responded to treatment were the lungs, lymph nodes, and brain. Major adverse effects included fever (86.8% of patients), anorexia (67.1%), fatigue (53.9%), and leukopenia (42.1%). No life‐threatening side effects appeared. High doses of recombinant human interferon gamma have an antitumor activity against renal cell carcinoma.